Background
The rapid advancement of cell and gene therapies has driven an exponential increase in demand for safe, high-quality viral vectors. Traditional plasmid DNA-based manufacturing processes, however, are often bottlenecked by complex fermentation, risks of endotoxin and bacterial DNA contamination, and high manufacturing costs. 4basebio’s hpDNA platform offers a promising solution to these critical issues, poised to alleviate significant manufacturing bottlenecks. Strategic partnerships with Contract Development and Manufacturing Organizations (CDMOs) like Genezen are pivotal for scaling this innovative technology and making it accessible to a broader spectrum of therapeutic developers, thereby accelerating the commercialization pathway for gene therapies.
Key Findings
4basebio and Genezen, a leading viral vector CDMO, have announced a strategic collaboration aimed at integrating 4basebio’s groundbreaking hpDNA platform into established viral vector manufacturing workflows. This integration is poised to dramatically enhance the production efficiency of critical viral vectors, specifically adeno-associated virus (AAV), demonstrating titer increases of up to 33-fold compared to conventional plasmid-based methods. This represents a significant breakthrough in overcoming persistent manufacturing cost and scalability hurdles, which remain major barriers to the broad commercialization and accessibility of gene therapies.
Technical Details
4basebio’s proprietary hpDNA platform employs an enzymatic, cell-free process to synthesize linear DNA constructs devoid of bacterial backbone sequences and antibiotic resistance genes. This ‘clean’ synthetic DNA not only achieves comparable or superior titers to traditional plasmid DNA in AAV production but also substantially reduces the required DNA mass and transfection reagent volumes by approximately 30%. Rigorous studies have confirmed that this optimized process reproducibly boosts crude harvest titers by an average of 10- to 33-fold across a diverse range of AAV capsid types. Genezen plans to integrate hpDNA, available in Research Use Only, High-Quality (HQ), and Good Manufacturing Practice (GMP)-grade formats, into its comprehensive viral vector development and manufacturing services. This technology is engineered to directly address the inherent complexities, high costs, and extended lead times typically associated with large-scale AAV manufacturing.
Strategic Outlook
The synergistic combination of 4basebio’s hpDNA platform and Genezen’s established manufacturing expertise holds immense potential to reshape the future landscape of gene therapy production. The anticipated significant improvements in manufacturing efficiency and cost-effectiveness are expected to accelerate the progression of a greater number of gene therapies from clinical development through to commercialization. This advancement will, in turn, accelerate the delivery of innovative gene therapies for a wide spectrum of indications, including rare diseases, various cancers, and other challenging conditions, to a broader global patient population. This collaboration is strategically poised to establish new benchmarks in viral vector manufacturing, thereby robustly supporting and catalyzing the growth of the entire gene therapy sector.
Source: https://allsci.com/news/licensing-and-partnerships/viral-vector-manufacturing-4basebio-and-genezen/
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments